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*Some numbered sections found in the Guidelines are not in-
cluded in this Summary because they do not include a guideline rec-
ommendationor an ‘‘In summary’’statement, or because thedetailed
information in the section was not suitable for a concise Summary.1.1. Overview
Food allergy (FA) is an important public health problem that
affects adults and children and may be increasing in prevalence.
Despite the risk of severe allergic reactions and even death, there
is no current treatment for FA: the disease can only bemanaged by
allergen avoidance or treatment of symptoms. Moreover, the
diagnosis of FA may be problematic, given that nonallergic food
reactions, such as food intolerance, are frequently confused with
FAs. Additional concerns relate to the differences in the diagnosis
and management of FA in different clinical practice settings.
Due to these concerns, the National Institute of Allergy and
Infectious Diseases (NIAID), part of the National Institutes of
Health, working with more than 30 professional organizations,
federal agencies, and patient advocacy groups, led the development
of ‘‘best practice’’ clinical guidelines for the diagnosis and
management of FA (henceforth referred to as the Guidelines).1
Based on a comprehensive review and objective evaluation of the
recent scientific and clinical literature on FA, the Guidelines
were developed by and designed for allergists/immunologists, clin-
ical researchers, and practitioners in the areas of pediatrics, family
medicine, internalmedicine, dermatology, gastroenterology, emer-
gency medicine, pulmonary and critical care medicine, and others.
The Guidelines focus on diseases that are defined as FA (see
section 2.1) and include both IgE-mediated reactions to food and
some non-IgE-mediated reactions to food. The Guidelines do not
discuss celiac disease, which is an immunologic non-IgE-
mediated reaction to certain foods. Although this is an immune-
based disease involving food, existing clinical guidelines for
celiac disease will not be restated here.
Finally, these Guidelines do not address the management of
patients with FA outside of clinical care settings (for example,
schools and restaurants) or the related public health policy issues.
These issues are beyond the scope of this document.
1.2. Relationship of the US Guidelines to other
guidelines
(Not summarized here; refer to Guidelines.)
1.3. How the Guidelines were developed and reviewed by the CC, the EP, and NIAID. The EP revised the
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Coordinating Committee (CC), whose members are listed in
Appendix A of the Guidelines, to oversee the development of the
Guidelines; review drafts of the Guidelines for accuracy, practi-
cality, clarity, and broad utility of the recommendations in clini-
cal practice; review the final Guidelines; and disseminate the
Guidelines. The CC members were from 34 professional organi-
zations, advocacy groups, and federal agencies, and each mem-
ber was vetted for financial conflict of interest (COI) by NIAID
staff.
1.3.2. The Expert Panel. The CC convened an Expert Panel
(EP) in March 2009 that was chaired by Joshua Boyce, MD
(Brigham and Women’s Hospital, Boston, Mass). Panel mem-
bers were specialists from a variety of relevant clinical,
scientific, and public health areas (see Acknowledgments).
Each member was vetted for financial COI by NIAID staff
and approved by the CC. The charge to the EP was to use an
independent, systematic literature review, in conjunction with
consensus expert opinion and EP-identified supplementary
documents, to develop Guidelines that provide a comprehensive
approach for diagnosing and managing FA based on the current
state of the science.
1.3.3. The independent, systematic literature review
and report. RAND Corporation prepared an independent,
systematic literature review and evidence report on the state of
the science in FA. This work was supported by an NIAID contract
awarded in September 2008. The contract’s principal investigator
was Paul G. Shekelle, MD, PhD, an internationally recognized
expert in the fields of practice guidelines and meta-analysis.
RAND screened more than 12,300 titles, reviewed more than
1,200 articles, abstracted nearly 900 articles, and included 348
articles in the final RAND report. The full version of the report
with a complete list of references is available at http://www.rand.
org/pubs/working_papers/WR757-1/.
1.3.4. Assessing the quality of the body of evidence. In
addition to assessing the quality of each of the included studies,
RAND assessed the quality of the body of evidence using the
Grading of Recommendations Assessment, Development and
Evaluation (GRADE) approach, which was developed in 2004.
GRADE provides a comprehensive and transparent methodology
to develop recommendations for the diagnosis, treatment, and
management of patients. In assessing the body of evidence,
GRADE considers study design and other factors, such as the
precision, consistency, and directness of the data. Using this
approach, GRADE then provides a grade of high, moderate, or
low for the quality of the body of evidence.
1.3.5. Preparation of the draft Guidelines and Expert
Panel deliberations. All 43 clinical recommendations drafted
by the EP received 90% (or higher) agreement. Sections 3, 5, and
6 of the Guidelines also contain ‘‘In summary’’ statements. These
statements are intended to provide health care professionals with
significant information that did not warrant a recommendation, or
are in place of a recommendation when the EP or the CC could not
reach consensus. All ‘‘In summary’’ statements received 90% (or
higher) agreement.
1.3.6. Public comment period and draft Guidelines
revision. The draft Guidelines were posted to the NIAID Web
site in March 2010 for a period of 60 days to allow for public
review and comment. More than 550 comments were collectedGuidelines in response to some of these comments. The final
Guidelines were published in the December 2010 issue of the
Journal of Allergy and Clinical Immunology and are publically
available at www.jacionline.org.
1.4. Defining the strength of each clinical guideline
The EP has used the verb ‘‘recommends’’ or ‘‘suggests’’ in each
clinical guideline. These words convey the strength of the
guideline, defined as follows:
d Recommend is used when the EP strongly recommended
for or against a particular course of action.
d Suggest is used when the EP weakly recommended for or
against a particular course of action.The Guidelines are intended to assist health care professionals
in making appropriate decisions about patient care in the United
States. The recommendations are not fixed protocols that must be
followed. Health care professionals should take these Guidelines
into account when exercising their clinical judgment. However,
this guidance does not override their responsibility to make
decisions appropriate to the circumstances of the individual
patient, in consultation with the patient, guardian, or caregiver.
Clinical judgment on the management of individual patients
remains paramount. Health care professionals, patients, and their
families need to develop individual treatment plans that are
tailored to the specific needs and circumstances of the patient.
This document is intended as a resource to guide clinical practice
and develop educational materials for patients, their families, and
the public. It is not an official regulatory document of any
government agency.EPIDEMIOLOGY OF FOOD ALLERGY
2.1. Definitions
2.1.1. Definitions of food allergy, food, and food
allergens. The EP came to consensus on definitions used
throughout the Guidelines.
A food allergy is defined as an adverse health effect arising
from a specific immune response that occurs reproducibly on ex-
posure to a given food.
A food is defined as any substance—whether processed, semi-
processed, or raw—that is intended for human consumption, and
includes drinks, chewing gum, food additives, and dietary supple-
ments. Substances used only as drugs, tobacco products, and cos-
metics (such as lip-care products) that may be ingested are not
included.
Food allergens are defined as those specific components of
food or ingredients within food (typically proteins, but some-
times also chemical haptens) that are recognized by allergen-
specific immune cells and elicit specific immunologic reactions,
resulting in characteristic symptoms. Some allergens (most of-
ten from fruits and vegetables) cause allergic reactions primarily
if eaten when raw. However, most food allergens can still cause
reactions even after they have been cooked or have undergone
digestion in the stomach and intestines. A phenomenon called
cross-reactivity may occur when an antibody reacts not only – Eosinophilic gastroenteritis
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FA, cross-reactivity occurs when a food allergen shares struc-
tural or sequence similarity with a different food allergen or
aeroallergen, which may then trigger an adverse reaction similar
to that triggered by the original food allergen. Cross-reactivity is
common, for example, among different shellfish and different
tree nuts.
Food oils—such as soy, corn, peanut, and sesame—range from
very low allergenicity (if virtually all of the food protein is
removed in processing) to very high allergenicity (if little of the
food protein is removed in processing).
2.1.2. Definitions of related terms. Because individuals can
develop allergic sensitization (as evidenced by the presence of
allergen-specific IgE (sIgE)) to food allergens without having
clinical symptoms on exposure to those foods, an sIgE-
mediated FA requires both the presence of sensitization and the
development of specific signs and symptoms on exposure to
that food. Sensitization alone is not sufficient to define FA.
TheseGuidelinesgenerally use the term tolerate todenote a con-
dition where an individual has either naturally outgrown an FA or
has received therapy and no longer develops clinical symptoms fol-
lowing ingestion of the food. This ability to tolerate food does not
distinguish between these 2 possible clinical states. Individuals
may tolerate food only for a short term, perhaps because they
have been desensitized by exposure to the food. Alternatively,
theymay develop long-term tolerance. The specific term tolerance
is used in these Guidelines to mean that an individual is symptom
free after consumption of the food or upon oral food challenge
weeks, months, or even years after the cessation of treatment.
The immunological mechanisms that underlie tolerance in humans
are poorly understood.
Although many different foods and food components have
been recognized as food allergens, these Guidelines focus on
only those foods that are responsible for the majority of
observed adverse allergic or immunologic reactions. Moreover,
foods or food components that elicit reproducible adverse
reactions but do not have established or likely immunologic
mechanisms are not considered food allergens. Instead, these
non-immunologic adverse reactions are termed food intoler-
ances. For example, an individual may be allergic to cow’s
milk (henceforth referred to as milk) due to an immunologic re-
sponse to milk protein, or alternatively, that individual may be
intolerant to milk due to an inability to digest the sugar lactose.
In the former situation, milk protein is considered an allergen
because it triggers an adverse immunologic reaction. Inability
to digest lactose leads to excess fluid production in the gastroin-
testinal (GI) tract, resulting in abdominal pain and diarrhea. This
condition is termed lactose intolerance, and lactose is not an al-
lergen because the response is not immune based. It should be
noted that the words tolerance and intolerance are unrelated
terms, even though the spelling of the words implies that they
are opposites.
2.1.3. Definitions of specific food-induced allergic con-
ditions. The reader is referred to the Guidelines for the
definitions of the following:
d Food-induced anaphylaxis
d GI food allergies and several specific syndromes
– Immediate GI hypersensitivity
– Eosinophilic esophagitis (EoE)– Food protein-induced allergic proctocolitis (AP)
– Food protein-induced enterocolitis syndrome (FPIES)
– Oral allergy syndrome (OAS)
d Cutaneous reactions to foods
– Acute urticaria
– Angioedema
– The increase in atopic dermatitis (AD) symptoms




2.2. Prevalence and epidemiology of food allergy
The true prevalence of FA has been difficult to establish for
several reasons.
d Although more than 170 foods have been reported to cause
IgE-mediated reactions, most prevalence studies have fo-
cused on only the most common foods.
d The incidence and prevalence of FA may have changed
over time, and many studies have indeed suggested a true
rise in prevalence over the past 10 to 20 years.
d Studies of FA incidence, prevalence, and natural history are
difficult to compare because of inconsistencies and defi-
ciencies in study design and variations in the definition of FA.
2.2.1. Systematic reviews of the prevalence of food
allergy. (Not summarized here; refer to Guidelines.)
2.2.2. Prevalence of allergy to specific foods, food-
induced anaphylaxis, and food allergy with comorbid
conditions. The following is a summary of prevalence data for
the most common food allergies and anaphylaxis:
Peanut
d Prevalence of peanut allergy in the United States is about
0.6% of the population.
d Prevalence of peanut allergy in France, Germany, Israel, Swe-
den, and theUnitedKingdomvaries between 0.06%and5.9%.
Tree nuts
d Prevalence of tree nut allergy in the United States is 0.4%
to 0.5% of the population.
d Prevalenceof tree nut allergy inFrance,Germany, Israel, Swe-
den, and theUnitedKingdomvaries between0.03%and8.5%.
Seafood
d Prevalence rates in the United States are significantly lower
for children than for adults: fish allergy, 0.2% for children
vs 0.5% for adults; crustacean shellfish allergy, 0.5% vs
2.5%; any seafood allergy, 0.6% vs 2.8%.
d Prevalence rates in the United States are higher for women
than for men: crustacean shellfish allergy, 2.6% for women
vs 1.5% for men; any fish, 0.6% vs 0.2%.
Milk and hen’s egg
d In a Danish cohort, allergy to milk was confirmed in 2.2%.
Of these, 54% had IgE-mediated allergy, and the remaining
46% were classified as non-IgE mediated.
d In a Norwegian cohort, the prevalence of hen’s egg (hence-
forth referred to as egg) allergy was estimated to be 1.6%,
and most egg reactions were IgE mediated.
Food-induced anaphylaxis 3.4. Natural history of conditions that coexist with
J ALLERGY CLIN IMMUNOL
DECEMBER 2010
1110 BOYCE ET ALd Several studies in the United States assessed the incidence
of anaphylaxis related to food. These studies found wide
differences in the rates (from 1/100,000 population to as
high as 70/100,000 population) of hospitalization or emer-
gency department visits for anaphylaxis, as assessed by In-
ternational Classification of Diseases, Ninth Revision,
Clinical Modification (ICD-9-CM) codes or medical record
review.
d The proportion of anaphylaxis cases thought to be due to
foods also varied between 13% and 65%, with the lowest
percentages found in studies that used more stringent diag-
nostic criteria for anaphylaxis.
The EP agreed that any estimate of the overall US incidence of
anaphylaxis is unlikely to have utility because such an estimate
fails to reflect the substantial variability in patient age, geographic
distribution, criteria used to diagnose anaphylaxis, and the study
methods used.SECTION 3. NATURAL HISTORY OF FOODALLERGY AND ASSOCIATED DISORDERS
The EP reviewed the literature on the natural history of FA
and summarized the available data for the most common food
allergens in the United States: egg, milk, peanut, tree nuts,
wheat, crustacean shellfish, and soy. Natural history data for
fish allergy were unavailable as of the completion of the
systematic literature review (September 2009). It should be
noted that many published studies addressing the natural history
of FA typically come from selected populations (for example,
from a single clinic or hospital) that may not be representative
of the general or community-based patient population with a
specific FA condition. Thus, the findings of these studies may
not necessarily be extrapolated to all patients with the
condition.3.1. Natural history of food allergy in childrenIn summary: Most children with FA eventually will tolerate
milk, egg, soy, and wheat; far fewer will eventually tolerate tree
nuts and peanut. The time course of FA resolution in children
varies by food and may occur as late as the teenage years.
A high initial level of sIgE against a food is associated with a
lower rate of resolution of clinical allergy over time.3.2. Natural history of levels of allergen-specific IgEto foods in children
In summary: For many patients, sIgE antibodies to foods
appear within the first 2 years of life. Levels may increase or
decrease; a decrease is often associated with the ability to tolerate
the foods.3.3. Natural history of food allergy in adults
SECTION 4. DIAGNOSIS OF FOOD ALLERGYIn summary: FA in adults can reflect persistence of pediatric
FAs (for example, milk, peanut, and tree nuts) or de novo sensiti-
zation to food allergens encountered after childhood. Although
there is a paucity of data from US studies, FA that starts in adult
life tends to persist.food allergy
In summary: FA may coexist with asthma, AD, EoE, and
exercise-induced anaphylaxis. In patients with asthma, the coex-
istence of FA may be a risk factor for severe asthma exacerba-
tions. Moreover, food may be a trigger for exercise-induced
anaphylaxis. Elimination of food allergens in sensitized individ-
uals can improve symptoms of some comorbid conditions.
3.4.1. Asthma.
In summary: Asthma and FA often coexist in pediatric and
adult patients. FA is associated with severe asthma.
3.4.2. Atopic dermatitis.
In summary: AD and FA are highly associated. When toler-
ance develops to a food, the reintroduction of the food in the
diet will not result in recurrence or worsening of the AD.
3.4.3. Eosinophilic esophagitis.
In summary: EoE is commonly associated with sensitization
to foods. The natural history of EoE is that of a chronic condi-
tion that resolves spontaneously or with therapy, and then re-
lapses. There are insufficient data to judge the impact of food
sensitization on the natural history of EoE, and vice versa.
Only retrospective data exist that support a beneficial effect of
dietary changes on the histopathologic changes in the esophagus
in EoE.
3.4.4. Exercise-induced anaphylaxis.
In summary: Exercise-induced anaphylaxis in adults is trig-
gered by foods in about one third of patients and has a natural his-
tory marked by frequent recurrence of the episodes.
3.5. Risk factors for the development of food allergyIn summary: Family history of atopy and the presence of AD
are risk factors for the development of both sensitization to food
and confirmed FA.
3.6. Risk factors for severity of allergic reactions to
foods
In summary: The severity of allergic reactions to foods is mul-
tifactorial and variable. The severity of a reaction cannot be accu-
rately predicted by the degree of severity of past reactions nor by
the level of sIgE or the size of the wheal from the skin prick test
(SPT). The factor most commonly identified with the most severe
reactions is the coexistence of asthma.
3.7. Incidence, prevalence, and consequences of
unintentional exposure to food allergens
In summary: Self-reported reactions to food frequently occur
in patients with a known diagnosis of FA. Although a subset of
these reactions is due to intentional exposure, most are due to un-
intentional exposure. Both types of exposure can be life-
threatening. There is no evidence that unintentional or inten-
tional exposures to the food allergen alter the natural history of
the FA.4.1. When should food allergy be suspected?
Guideline 1: The EP recommends that FA should be
considered:
d In individuals presenting with anaphylaxis or any com-
4.2. Diagnosis of IgE-mediated food allergyTABLE I. Symptoms of food-induced allergic reactions




































































Note: This table is presented as Table IV in the Guidelines.
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within minutes to hours of ingesting food, especially
in young children and/or if symptoms have followed
the ingestion of a specific food on more than
1 occasion
d In infants, young children, and selected older children
diagnosed with certain disorders, such as moderate to se-
vere AD, EoE, enterocolitis, enteropathy, and allergic
proctocolitis
d In adults diagnosed with EoE4.2.1. Medical history and physical examination.
Guideline 2: The EP recommends using medical history and
physical examination to aid in the diagnosis of FA.
d Medical history: The EP recommends using a detailed
medical history to help focus the evaluation of an FA. Al-
though the medical history often provides evidence for
the type of food-induced allergic reaction and the potential
causative food(s) involved, history alone cannot be consid-
ered diagnostic of FA.
d Physical examination: The EP recommends performing a
focused physical examination of the patient, which may
provide signs consistent with an allergic reaction or disor-
der often associated with FA. However, by itself, the phys-
ical examination cannot be considered diagnostic of FA.
Guideline 3: The EP recommends that parent and patient re-
ports of FA must be confirmed, because multiple studies demon-
strate that 50% to 90% of presumed FAs are not allergies.
4.2.2. Methods to identify the causative food.
4.2.2.1. Skin prick test.
Guideline 4: The EP recommends performing an SPT (also
known as a skin puncture test) to assist in the identification of
foods that may be provoking IgE-mediated food-induced allergic
reactions, but the SPT alone cannot be considered diagnostic
of FA.
4.2.2.2. Intradermal tests.
Guideline 5:TheEPrecommends that intradermal testing should
not be used to make a diagnosis of FA.
4.2.2.3. Total serum IgE.
Guideline 6: The EP recommends that the routine use of mea-
suring total serum IgE should not be used to make a diagnosis of
FA.
4.2.2.4. Allergen-specific serum IgE.
Guideline 7: The EP recommends sIgE tests for identifying
foods that potentially provoke IgE-mediated food-induced aller-
gic reactions, but alone these tests are not diagnostic of FA.
4.2.2.5. Atopy patch test.
Guideline 8: The EP suggests that the atopy patch test (APT)
should not be used in the routine evaluation of non-contact FA.
4.2.2.6. Use of skin prick tests, sIgE tests, and atopy
patch tests in combination.
Guideline 9: The EP suggests not using the combination of
SPTs, sIgE tests, and APTs for the routine diagnosis of FA.
4.2.2.7. Food elimination diets.
Guideline 10: TheEP suggests that elimination of 1 or a few spe-
cific foods from the diet may be useful in the diagnosis of FA, espe-
cially in identifying foods responsible for some non-IgE-mediated
food-induced allergic disorders, such as FPIES, AP, and Heiner syn-
drome, and some mixed IgE- and non-IgE-mediated food-induced
allergic disorders, such as EoE.
4.2.2.8. Oral food challenges.
Guideline 11: The EP recommends using oral food challenges
for diagnosing FA. The double-blind placebo-controlled food
challenge is the gold standard. However, a single-blind or an
open-food challenge may be considered diagnostic under certain
circumstances: if either of these challenges elicits no symptoms
(ie, the challenge is negative), then FA can be ruled out; but
when either challenge elicits objective symptoms (ie, the chal-
lenge is positive) and those objective symptoms correlate with
medical history and are supported by laboratory tests, then a diag- Contact urticaria can be of 2 types, either IgE mediated or non-
SECTION 5. MANAGEMENT OF NONACUTE
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4.2.2.9. Nonstandardized and unproven procedures.
Guideline 12: The EP recommends not using any of the follow-
ing nonstandardized tests for the routine evaluation of IgE-mediated
FA:
d Basophil histamine release/activation
d Lymphocyte stimulation
d Facial thermography
d Gastric juice analysis






d Electrodermal test (Vega)
d Mediator release assay (LEAP diet)
4.3. Diagnosis of non-IgE-mediated immunologic ad-
verse reactions to food.
4.3.1. Eosinophilic gastrointestinal diseases.
Guideline 13: The EP suggests that SPTs, sIgE tests, and APTs
may be considered to help identify foods that are associated with
EoE, but these tests alone are not sufficient to make the diagnosis
of FA. The role of these tests in the diagnosis of other eosinophilic
GI disorders has not been established.
4.3.2. Food protein-induced enterocolitis syndrome.
Guideline 14: The EP recommends using the medical history
and oral food challenge to establish a diagnosis of FPIES. How-
ever, when history indicates that infants or children have experi-
enced hypotensive episodes or multiple reactions to the same
food, a diagnosis may be based on a convincing history and ab-
sence of symptoms when the causative food is eliminated from
the diet.
4.3.3. Food protein-induced allergic proctocolitis.
Guideline 15: The EP recommends using the medical history,
resolution of symptoms when the causative food is eliminated
from the diet, and recurrence of symptoms following an oral
food challenge to diagnose allergic proctocolitis.
4.3.4. Food protein-induced enteropathy syndrome.
(Not summarized here; refer to Guidelines.)
4.3.5. Allergic contact dermatitis.
Guideline 16: The EP recommends using the medical history,
including the absence of symptoms while the causative food is
avoided, and positive patch tests to diagnose allergic contact
dermatitis.
4.3.6. Systemic contact dermatitis.
Guideline 17: The EP suggests using the medical history, in-
cluding the resolution of symptoms while the causative food is
avoided, and positive patch tests to establish the diagnosis of sys-
temic contact dermatitis.
4.4. Diagnosis of IgE-mediated contact urticaria
Guideline 18: The EP suggests using the medical history, in-
cluding the absence of symptoms while the causative food is
avoided, positive sIgE tests or SPTs, and positive immediate epi-
cutaneous skin tests (for example, positive immediate responses
to APTs), to establish the diagnosis of food-induced IgE-
mediated contact urticaria.IgE mediated. In IgE-mediated contact urticaria, substances
present in foods interact with sIgE bound to cutaneous mast
cells, leading to the release of histamine and other inflammatory
mediators. Localized or generalized urticaria, as well as systemic
symptoms, may result. sIgE-mediated contact urticaria may be
assessed with APTs, SPTs, or sIgE tests, although there is no
standardization of diagnostic methodology. In non-IgE-mediated
contact urticaria to food, systemic symptoms are rarely seen.ALLERGIC REACTIONS AND PREVENTION OF
FOOD ALLERGY
5.1. Management of individuals with food allergy
5.1.1. Dietary avoidance of specific allergens in IgE-
mediated food allergy.
Guideline 19: The EP recommends that individuals with docu-
mented IgE-mediated FA should avoid ingesting their specific al-
lergen or allergens.
5.1.2. Dietary avoidance of specific allergens in non-
IgE-mediated food allergy.
Guideline 20: The EP recommends that individuals with docu-
mented non-IgE-mediated FA should avoid ingesting their spe-
cific allergen or allergens.
5.1.3. Effects of dietary avoidance on associated and
comorbid conditions, such as atopic dermatitis,
asthma, and eosinophilic esophagitis.
Guideline 21: In individualswithdocumentedor provenFAwho
also have 1 ormore of the following—AD, asthma, or EoE—theEP
recommends avoidance of their specific allergen or allergens.
Guideline 22: In individuals without documented or proven
FA, the EP does not recommend avoiding potentially allergenic
foods as a means of managing AD, asthma, or EoE.
5.1.4. Food avoidance and nutritional status.
Guideline 23: The EP recommends nutritional counseling and
regular growth monitoring for all children with FA.
5.1.5. Food labeling in food allergy management.
Guideline 24: The EP suggests that individuals with FA and
their caregivers receive education and training on how to interpret
ingredient lists on food labels and how to recognize labeling of the
food allergens used as ingredients in foods. The EP also suggests
that products with precautionary labeling, such as ‘‘this product
may contain trace amounts of allergen,’’ be avoided.
5.1.6. When to re-evaluate patients with food allergy.
Guideline 25: The EP suggests follow-up testing for individ-
uals with FA depending on the specific food to which the individ-
ual is allergic. Whether testing is done annually or at other
intervals depends on the food in question, the age of the child,
and the intervening medical history.
5.1.7. Pharmacologic intervention for the prevention of
food-induced allergic reactions.
5.1.7.1. IgE-mediated reactions.
Guideline 26: There are no medications currently recommen-
ded by the EP to prevent IgE-mediated food-induced allergic reac-
tions from occurring in an individual with existing FA.
5.1.7.2. Non-IgE-mediated reactions.
Guideline 27: There are no medications currently recommen-
ded by the EP to prevent non-IgE-mediated food-induced allergic
reactions from occurring in an individual with existing FA.
5.1.8. Pharmacologic intervention for the treatment of among the very patients who would highly benefit from influenza
5.2. Management of individuals at risk for food
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first line of treatment for FA, and use of antihistamines, as needed,
remains the mainstay of managing (as opposed to preventing)
symptoms of nonsevere food-induced allergic reactions. How-
ever, drug therapy has been used to treat FA in cases where
allergen avoidance is extremely difficult or results in nutritional
deficiencies. Drugs that alter the immune response to the allergen
are commonly considered the most likely candidates for such
therapy in the future, but these treatments are not currently
recommended (see Guideline 28).
5.1.9. Immunotherapy for food allergy management.
5.1.9.1. Allergen-specific immunotherapy.
Guideline 28: The EP does not recommend using allergen-
specific immunotherapy to treat IgE-mediated FA.
5.1.9.2. Immunotherapy with cross-reactive allergens.
Guideline 29: The EP does not recommend immunotherapy
with cross-reactive allergens for treating IgE-mediated FA.
5.1.10. Quality-of-life issues associated with food
allergy.
Guideline 30: The EP recommends that patients with FA and
their caregivers be provided with information on food allergen
avoidance and emergency management that is age and culturally
appropriate.
5.1.11. Vaccinations in patients with egg allergy.
In summary: Patients who have generated IgE antibodies to an
allergen are at risk for anaphylaxis with systemic exposure to that
allergen. Thus, patients who have IgE-mediated egg allergy are at
risk for anaphylaxis if injected with vaccines containing egg pro-
tein. More detailed information about specific egg-containing vac-
cines (MMR, MMRV, influenza, yellow fever, and rabies) is
provided in sections 5.1.11.1-5.1.11.4 of the Guidelines.
The EP recognizes that changes in these recommendations may
occur in the future as there is an increased understanding of the risk
factors for allergic reactions andasvaccinemanufacturingprocesses
improve and decrease the final egg protein content of vaccines. For
themost current recommendations, health care professionals should
refer to theWeb sites of theAmericanAcademyof Pediatrics (AAP)
and Advisory Committee for Immunization Practices (ACIP):
d http://aapredbook.aappublications.org/
d http://www.cdc.gov/vaccines/recs/acip/
5.1.11.1. Measles, mumps, rubella, and varicella
vaccine.
Guideline 31: The EP recognizes the varying consensus rec-
ommendations of the different organizations on this particular
vaccine and recommends that children with egg allergy, even
those with a history of severe reactions, receive vaccines for mea-
sles, mumps, and rubella (MMR) and for MMR with varicella
(MMRV). The safety of this practice has been recognized by
ACIP and AAP and is noted in the approved product prescribing
information for these vaccines.
5.1.11.2. Influenza vaccine.
In summary: The EP concludes that insufficient evidence ex-
ists to recommend administering influenza vaccine, either inacti-
vated or live-attenuated, to patients with a history of severe
reactions to egg proteins. Severe reactions include a history of
hives, angioedema, allergic asthma, or systemic anaphylaxis to
egg proteins (or chicken proteins). Less severe or local manifes-
tations of allergy to egg or feathers are not contraindications.
However, the EP notes that egg allergy is relatively commonvaccination. Such patients include children and young adults
(from 6 months to 18 years old for seasonal influenza, and from
6 months to 24 years old for H1N1 influenza) and all patients
with asthma. It should be noted that live-attenuated vaccine is
not licensed for use in patients with asthma.
Although ACIP and AAP, and also the vaccine manufacturers,
do not recommend influenza vaccination in patients who are
allergic to egg, several publications have described different
approaches to giving the influenza vaccine to patients with severe
allergic reactions to egg. These approaches, which depend on the
ovalbumin content and the results of SPTs or intradermal tests
with the vaccine, include a single dose of vaccine, 2 doses of
vaccine, or multiple doses. However, the evidence supporting
these approaches is limited by the small numbers of patients
included in each study. Moreover, data indicate that, although the
vaccines are relatively safe, there remains some, albeit low, risk of
systemic reactions. Also, negative SPT results do not accurately
predict safety of vaccination, in that 5% of patients with negative
SPTs had systemic reactions to vaccination.
5.1.11.3. Yellow fever vaccine.
In summary: The EP recognizes the current guidelines from
the different organizations and recommends against administer-
ing yellow fever vaccine to patients with a history of hives, angi-
oedema, allergic asthma, or systemic anaphylaxis to egg proteins,
unless an allergy evaluation and testing with the vaccine is done
first. This approach has been recognized by ACIP and AAP and
is noted in the approved product prescribing information for
this vaccine.
5.1.11.4. Rabies vaccines.
In summary: The EP recognizes the current guidelines from
the different organizations and recommends against administer-
ing rabies vaccines to patients with a history of hives, angioe-
dema, allergic asthma, or systemic anaphylaxis to egg proteins,
unless an allergy evaluation and testing with the vaccine is done
first. This approach has been recognized by ACIP and AAP and
is noted in the approved product prescribing information for these
vaccines.allergy
5.2.1. Nonfood allergen avoidance in at-risk patients.
Guideline 32: The EP suggests that patients at risk for develop-
ing FA do not limit exposure to potential nonfood allergens (for ex-
ample, dust mites, pollen, or pet dander). Patients at risk for
developing FA are defined as those with a biological parent or sib-
lingwith existing, or history of, allergic rhinitis, asthma,AD, or FA.
This definition of ‘‘at risk’’ is used throughout sections 5.2 and 5.3.
5.2.2. Dietary avoidance of foods with cross-
reactivities in at-risk patients.
Guideline 33: The EP suggests that patients at risk for devel-
oping FA do not need to limit exposure to foods that may be
cross-reactivewith the 8 major food allergens in the United States
(milk, egg, peanut, tree nuts, soy, wheat, fish, and crustacean
shellfish).
5.2.3. Testing of allergenic foods in patients at high
risk prior to introduction.
In summary: The EP concludes that insufficient evidence ex-
ists to recommend routine FA testing prior to the introduction of
highly allergenic foods (such as milk, egg, and peanut) in children
who are at high risk of reacting to the introduction of such foods. SECTION 6. DIAGNOSIS AND MANAGEMENT OF
6.2. Diagnosis of acute, life-threatening, food-
6.3. Treatment of acute, life-threatening, food-
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children with pre-existing severe allergic disease and/or a family
history of FA. Nevertheless, there may be some value in FA eval-
uations that include an oral food challenge for a select group of pa-
tients with certain risk factors, such as having a sibling with peanut
allergy or evidence of another underlying FA (for example, testing
for tree nut allergy in a child with peanut allergy). It is possible that
an FA evaluation prior to introduction of a food could potentially
prevent allergic reactions. However, widespread SPTs and sIgE
tests are not recommended because of their poor predictive value.
These tests would lead to many clinically irrelevant results and un-
necessary dietary restrictions, especially if unconfirmed by oral
food challenges. Overall, the risk-to-benefit ratio of FA evaluation
should be considered on an individual basis, especially for the
highly allergenic foods in high-risk young children.
Guideline 34: The EP suggests that the general population of
children not be tested for FA to highly allergenic foods prior to
their introduction into the diet. The general population of children
does not have pre-existing severe allergic disease and also does
not have a family history of FA.
5.2.4. Testing in infants and children with persistent
atopic dermatitis.
Guideline 35: The EP suggests that children less than 5 years
old with moderate to severe AD be considered for FA evaluation
for milk, egg, peanut, wheat, and soy, if at least 1 of the following
conditions is met:
d The child has persistent AD in spite of optimized manage-
ment and topical therapy.
d The child has a reliable history of an immediate reaction af-
ter ingestion of a specific food.
5.3. Prevention of food allergy
5.3.1. Maternal diet during pregnancy and lactation.
Guideline 36: The EP does not recommend restricting mater-
nal diet during pregnancy or lactation as a strategy for preventing
the development or clinical course of FA.
5.3.2. Breast-feeding.
Guideline 37: The EP recommends that all infants be exclu-
sively breast-fed until 4 to 6 months of age, unless breast-
feeding is contraindicated for medical reasons.
5.3.3. Special diets in infants and young children.
5.3.3.1. Soy infant formula versus cow’s milk formula.
Guideline 38: The EP does not recommend using soy infant
formula instead of cow’s milk infant formula as a strategy for pre-
venting the development of FA or modifying its clinical course in
at-risk infants (‘‘at risk’’ is defined in Guideline 32).
5.3.3.2. Hydrolyzed infant formulas versus cow’s milk
formula or breast-feeding.
Guideline 39: The EP suggests that the use of hydrolyzed in-
fant formulas, as opposed to cow’s milk formula, may be consid-
ered as a strategy for preventing the development of FA in at-risk
infants who are not exclusively breast-fed (‘‘at risk’’ is defined in
Guideline 32). Cost and availability of extensively hydrolyzed in-
fant formulas may be weighed as prohibitive factors.
5.3.4. Timing of introduction of allergenic foods to
infants.
Guideline 40: The EP suggests that the introduction of solid
foods should not be delayed beyond 4 to 6 months of age. Poten-
tially allergenic foods may be introduced at this time as well.FOOD-INDUCED ANAPHYLAXIS AND OTHER
ACUTE ALLERGIC REACTIONS TO FOODS
6.1. Definition of anaphylaxis
Anaphylaxis is defined as a serious allergic reaction that is
rapid in onset and may cause death. Typically, IgE-mediated
food-induced anaphylaxis is believed to involve systemic mediator
release from sensitized mast cells and basophils. The term ana-
phylactoid has been used in the past to indicate adverse reactions
that are not IgE mediated and typically are not life-threatening.
This term is imprecise and will not be used in these Guidelines.induced allergic reactions
Guideline 41: The EP recommends that the health care profes-
sional considering a diagnosis of food-induced anaphylaxis
should understand:
d The signs and symptoms characteristic of anaphylaxis
d The timing of symptoms in association with food ingestion/
exposure
d Comorbid conditions, such as asthma, that may affect treat-
ment and outcome
d The limited utility of laboratory parameters in the acute-
care settinginduced allergic reactions
6.3.1. First-line and adjuvant treatment for food-
induced anaphylaxis.
Guideline 42: The EP recommends that treatment for food-
induced anaphylaxis should focus on the following:
d Prompt and rapid treatment after onset of symptoms (see
Table II)
d Intramuscular (IM) epinephrine as first-line therapy
d Other treatments, which are adjunctive to epinephrine
dosing
Epinephrine is the first-line treatment in all cases of anaphy-
laxis. All other drugs have a delayed onset of action. When there
is suboptimal response to the initial dose of epinephrine, or if
symptoms progress, repeat epinephrine dosing remains first-line
therapy over adjunctive treatments.
The cornerstones of initial management should begin with the
following concurrent steps:
d Elimination of additional allergen exposure
d IM injection of epinephrine
d Call for help (summon a resuscitation team in the hospital
setting, call 911 or an equivalent service in the community
setting), although attempts to summon help should not de-
lay use of epinephrine
These actions should be quickly followed by these additional
steps:
d Placement of the patient in a recumbent position (if toler-
ated), with the lower extremities elevated
d Provision of supplemental oxygen
d Administration of intravenous (IV) fluid (volume resuscita-
tion)
TABLE II. Summary of the pharmacologic management of anaphylaxis (modified)
Note: These treatments often occur concomitantly, and are not meant to be sequential, with the exception of epinephrine as first-line treatment.
In the outpatient setting
d First-line treatment:
– Epinephrine, IM; auto-injector or 1:1,000 solution
B Weight 10 to 25 kg: 0.15 mg epinephrine autoinjector, IM (anterior-lateral thigh)
B Weight >25 kg: 0.3 mg epinephrine autoinjector, IM (anterior-lateral thigh)
B Epinephrine (1:1,000 solution) (IM), 0.01 mg/kg per dose; maximum dose, 0.5 mg per dose (anterior-lateral thigh)
–Epinephrine doses may need to be repeated every 5-15 minutes
dAdjunctive treatment:
–Bronchodilator (b2-agonist): albuterol
B MDI (child: 4-8 puffs; adult: 8 puffs) or
B Nebulized solution (child: 1.5 ml; adult: 3 ml) every 20 minutes or continuously as needed
–H1 antihistamine: diphenhydramine
B 1 to 2 mg/kg per dose
B Maximum dose, 50 mg IV or oral (oral liquid is more readily absorbed than tablets)
B Alternative dosing may be with a less-sedating second generation antihistamine
– Supplemental oxygen therapy
– IV fluids in large volumes if patient presents with orthostasis, hypotension, or incomplete response to IM epinephrine
– Place the patient in recumbent position if tolerated, with the lower extremities elevated
In the hospital-based setting
d First-line treatment:
– Epinephrine IM as above, consider continuous epinephrine infusion for persistent hypotension (ideally with continuous non-invasive monitoring of
blood pressure and heart rate); alternatives are endotracheal or intra-osseous epinephrine
d Adjunctive treatment:
– Bronchodilator (b2-agonist): albuterol
B MDI (child: 4-8 puffs; adult: 8 puffs) or
B Nebulized solution (child: 1.5 ml; adult: 3 ml) every 20 minutes or continuously as needed
– H1 antihistamine: diphenhydramine
B 1 to 2 mg/kg per dose
B Maximum dose, 50 mg IV or oral (oral liquid is more readily absorbed than tablets)
B Alternative dosing may be with a less-sedating second generation antihistamine
– H2 antihistamine: ranitidine
B 1 to 2 mg/kg per dose
B Maximum dose, 75 to 150 mg oral and IV
– Corticosteroids
B Prednisone at 1 mg/kg with a maximum dose of 60 to 80 mg oral or
B Methylprednisolone at 1 mg/kg with a maximum dose of 60 to 80 mg IV
– Vasopressors (other than epinephrine) for refractory hypotension, titrate to effect
– Glucagon for refractory hypotension, titrate to effect
B Child: 20-30 mg/kg
B Adult: 1-5 mg
B Dose may be repeated or followed by infusion of 5-15 mg/min
– Atropine for bradycardia, titrate to effect
– Supplemental oxygen therapy
– IV fluids in large volumes if patients present with orthostasis, hypotension, or incomplete response to IM epinephrine
– Place the patient in recumbent position if tolerated, with the lower extremities elevated
Therapy for the patient at discharge
d First-line treatment:
– Epinephrine auto-injector prescription (2 doses) and instructions
– Education on avoidance of allergen
– Follow-up with primary care physician
– Consider referral to an allergist
d Adjunctive treatment:
– H1 antihistamine: diphenhydramine every 6 hours for 2-3 days; alternative dosing with a non-sedating second generation antihistamine
– H2 antihistamine: ranitidine twice daily for 2-3 days
– Corticosteroid: prednisone daily for 2-3 days
IM, Intramuscular; IV, intravenous; MDI, metered-dose inhaler.
Note: This table is presented as Table VI in the Guidelines.
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APPENDIX A. PRIMARY AUTHOR AFFILIATIONS
J ALLERGY CLIN IMMUNOL
DECEMBER 2010
1116 BOYCE ET ALreason reported for not using epinephrine and may place a patient
at significantly increased risk for progression toward a life-
threatening reaction.
6.3.2. Treatment of refractory anaphylaxis. No published
prospective studies exist on the optimal management of refractory
anaphylactic shock. Repeated use of epinephrine, as well as IV
fluids, corticosteroids, and vasopressor agents, may be needed.
Prompt transfer to an acute-care facility and intensive-care unit
for treatment and monitoring is essential.
6.3.3. Possible risks of acute therapy for anaphylaxis.
There are no absolute contraindications to epinephrine use in
anaphylaxis. However, there are subgroups of patients who might
theoretically be at higher risk for adverse effects during epineph-
rine therapy. Because the risk of death or serious disability from
anaphylaxis itself usually outweighs other concerns, existing
evidence clearly favors the benefit of epinephrine administration
in most situations. Some level of decision making regarding the
risk-to-benefit ratio may be warranted for patients under specific
circumstances (described in the Guidelines).
6.3.4. Treatment to prevent biphasic or protracted food-
induced allergic reactions. Very little information exists that
defines the mechanism of biphasic or protracted allergic reac-
tions. Similarly, little information exists to support specific
therapy to prevent biphasic or protracted food-induced allergic
reactions. In general, induction and recruitment of inflammatory
cells and release of preformed, long-acting mediators from
mast cells have been implicated as mechanisms. Due to their
anti-inflammatory properties, systemic corticosteroids are often
recommended to prevent biphasic or protracted food-induced
allergic reactions, but little data support their use.
6.3.5. Management of milder, acute food-induced al-
lergic reactions in health care settings. Milder forms of
allergic reactions, such as flushing, urticaria, isolated mild
angioedema, or symptoms of OAS, can be treated with H1 and
H2 antihistamine medications. When antihistamines alone are
given, ongoing observation and monitoring are warranted to en-
sure a lack of progression to more significant symptoms of ana-
phylaxis. If progression or increased severity is noted,
epinephrine should be administered immediately. Additionally,
if there is a history of a prior severe allergic reaction, epinephrine
should be administered promptly and earlier in the course of treat-
ment (for example, at the onset of even mild symptoms).
6.4. Management of food-induced anaphylaxisGuideline 43: The EP recommends that the management of
food-induced anaphylaxis should focus on the following:
d Dosing with IM epinephrine followed by transfer to an emer-
gency facility for observation and possible further treatment
d Observation for 4 to 6 hours or longer based on severity of
the reaction
d Education for patient and family on:
– Allergen avoidance
– Early recognition of signs and symptoms of anaphylaxis
– Anaphylaxis emergency action plan implementation
– Appropriate IM epinephrine administration
– Medical identification jewelry or an anaphylaxis wallet
card
d Epinephrine auto-injector prescription and training pro-
vided at the time of dischargedischarge:
– H1 antihistamine: diphenhydramine every 6 hours for 2-
3 days; alternative dosing with a non-sedating second
generation antihistamine
– H2 antihistamine: ranitidine twice daily for 2-3 days
– Corticosteroid: prednisone daily for 2-3 days
d Follow-up appointment with primary health care profes-
sional (after the food-induced anaphylactic reaction), with
consideration for additional follow-up with a clinical spe-
cialist such as an allergist/immunologist
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